BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 34586737)

  • 1. RNA N
    Zhang Z; Zhang C; Luo Y; Zhang G; Wu P; Sun N; He J
    Clin Transl Med; 2021 Sep; 11(9):e525. PubMed ID: 34586737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surmounting cancer drug resistance: New insights from the perspective of N
    Li B; Jiang J; Assaraf YG; Xiao H; Chen ZS; Huang C
    Drug Resist Updat; 2020 Dec; 53():100720. PubMed ID: 32892147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N
    Quan C; Belaydi O; Hu J; Li H; Yu A; Liu P; Yi Z; Qiu D; Ren W; Ma H; Gong G; Ou Z; Chen M; Sun Y; Chen J; Zu X
    Front Immunol; 2021; 12():697026. PubMed ID: 34526985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cross-talk of four types of RNA modification writers defines tumor microenvironment and pharmacogenomic landscape in colorectal cancer.
    Chen H; Yao J; Bao R; Dong Y; Zhang T; Du Y; Wang G; Ni D; Xun Z; Niu X; Ye Y; Li HB
    Mol Cancer; 2021 Feb; 20(1):29. PubMed ID: 33557837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of m
    Wu C; Li L; Tang Q; Liao Q; Chen P; Guo C; Zeng Z; Xiong W
    Med Oncol; 2024 May; 41(6):159. PubMed ID: 38761335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The N
    Zhao R; Li B; Zhang S; He Z; Pan Z; Guo Q; Qiu W; Qi Y; Zhao S; Wang S; Chen Z; Zhang P; Guo X; Xue H; Li G
    Front Immunol; 2021; 12():653711. PubMed ID: 34354698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RNA Modifications in Cancer Stem Cell Biology.
    Cerneckis J; Cui Q; Liu W; Shi Y
    Cancer Treat Res; 2023; 190():25-47. PubMed ID: 38112998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Challenges and opportunities for cancer stem cell-targeted immunotherapies include immune checkpoint inhibitor, cancer stem cell-dendritic cell vaccine, chimeric antigen receptor immune cells, and modified exosomes.
    Alqarni A; Jasim SA; Altalbawy FMA; Kaur H; Kaur I; Rodriguez-Benites C; Deorari M; Alwaily ER; Al-Ani AM; Redhee AH
    J Biochem Mol Toxicol; 2024 Jun; 38(6):e23719. PubMed ID: 38764138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N6-Methyladenosine RNA Modification in the Tumor Immune Microenvironment: Novel Implications for Immunotherapy.
    Guo L; Yang H; Zhou C; Shi Y; Huang L; Zhang J
    Front Immunol; 2021; 12():773570. PubMed ID: 34956201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RNA N6-methyladenosine modification in regulating cancer stem cells and tumor immune microenvironment and its implication for cancer therapy.
    Kumari S; Kumar S; Muthuswamy S
    J Cancer Res Clin Oncol; 2023 Apr; 149(4):1621-1633. PubMed ID: 35796777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. m
    Sun M; Xie M; Zhang T; Wang Y; Huang W; Xia L
    Front Immunol; 2021; 12():739768. PubMed ID: 34616403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in Therapeutic Targeting of Cancer Stem Cells within the Tumor Microenvironment: An Updated Review.
    Dzobo K; Senthebane DA; Ganz C; Thomford NE; Wonkam A; Dandara C
    Cells; 2020 Aug; 9(8):. PubMed ID: 32823711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. One Stone, Two Birds: N6-Methyladenosine RNA Modification in Leukemia Stem Cells and the Tumor Immune Microenvironment in Acute Myeloid Leukemia.
    Ouyang X; Gong Y
    Front Immunol; 2022; 13():912526. PubMed ID: 35720276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new perspective on hematological malignancies: m6A modification in immune microenvironment.
    Yang S; Xu L; Zhuang H; Li F; Lu Y
    Front Immunol; 2024; 15():1374390. PubMed ID: 38868768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stem cell programs in cancer initiation, progression, and therapy resistance.
    Huang T; Song X; Xu D; Tiek D; Goenka A; Wu B; Sastry N; Hu B; Cheng SY
    Theranostics; 2020; 10(19):8721-8743. PubMed ID: 32754274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the RNA m
    Li X; Ma S; Deng Y; Yi P; Yu J
    Mol Cancer; 2022 Mar; 21(1):76. PubMed ID: 35296338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. m
    Chong W; Shang L; Liu J; Fang Z; Du F; Wu H; Liu Y; Wang Z; Chen Y; Jia S; Chen L; Li L; Chen H
    Theranostics; 2021; 11(5):2201-2217. PubMed ID: 33500720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive Analysis of m6A RNA Methylation Regulators and the Immune Microenvironment to Aid Immunotherapy in Pancreatic Cancer.
    Guo Y; Wang R; Li J; Song Y; Min J; Zhao T; Hua L; Shi J; Zhang C; Ma P; Yang C; Zhu L; Gan D; Li S; Liu X; Su H
    Front Immunol; 2021; 12():769425. PubMed ID: 34804059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biological and pharmacological roles of m
    Liu Z; Zou H; Dang Q; Xu H; Liu L; Zhang Y; Lv J; Li H; Zhou Z; Han X
    Mol Cancer; 2022 Dec; 21(1):220. PubMed ID: 36517820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The bad seed: Cancer stem cells in tumor development and resistance.
    Koren E; Fuchs Y
    Drug Resist Updat; 2016 Sep; 28():1-12. PubMed ID: 27620951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.